TY  - JOUR
AU  - Höglinger, Günter U
AU  - Lang, Anthony E
TI  - The why and how of the SynNerGe criteria of Parkinson´s disease.
JO  - Journal of neural transmission
VL  - 131
IS  - 10
SN  - 0375-9245
CY  - Wien [u.a.]
PB  - Springer
M1  - DZNE-2024-01255
SP  - 1149 - 1154
PY  - 2024
AB  - In pursuit of early therapeutic interventions for Parkinson's disease, the proposed SynNeurGe classification system integrates α-synuclein pathology (S), neurodegeneration evidence (N), and pathogenic gene variants (G). This approach aims to address the disease's complexity and biological diversity. It suggests categorizing patients based on the presence or absence of α-synuclein pathology in tissues or cerebrospinal fluid, neurodegeneration indicators from specific imaging techniques, and identification of pathogenic gene variants associated with Parkinson's disease. The proposed system emphasizes the future need for precision medicine and aims to facilitate both basic and clinical research toward disease-modifying therapies. However, the authors stress that initial implementation should be confined to research settings, considering ethical implications and current limitations. Prospective validation of these criteria is deemed necessary to ensure their efficacy and ethical application in clinical practice.
KW  - Humans
KW  - Parkinson Disease: diagnosis
KW  - Parkinson Disease: genetics
KW  - alpha-Synuclein: metabolism
KW  - alpha-Synuclein: cerebrospinal fluid
KW  - Biological definition (Other)
KW  - Genetics (Other)
KW  - Neurodegeneration (Other)
KW  - Parkinson’s disease (Other)
KW  - Synuclein (Other)
KW  - alpha-Synuclein (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:38916622
C2  - pmc:PMC11489162
DO  - DOI:10.1007/s00702-024-02797-9
UR  - https://pub.dzne.de/record/272837
ER  -